Voya Investment Management LLC Has $128.95 Million Holdings in CVS Health Co. (NYSE:CVS)

Voya Investment Management LLC raised its position in CVS Health Co. (NYSE:CVS - Free Report) by 331.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,872,542 shares of the pharmacy operator's stock after purchasing an additional 2,206,299 shares during the quarter. Voya Investment Management LLC owned 0.23% of CVS Health worth $128,948,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Adage Capital Partners GP L.L.C. increased its position in shares of CVS Health by 2.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,192,774 shares of the pharmacy operator's stock valued at $53,544,000 after acquiring an additional 26,738 shares during the last quarter. Syon Capital LLC increased its position in shares of CVS Health by 3.4% during the 4th quarter. Syon Capital LLC now owns 7,526 shares of the pharmacy operator's stock worth $338,000 after purchasing an additional 247 shares during the last quarter. Coppell Advisory Solutions LLC raised its stake in shares of CVS Health by 17.3% during the 4th quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator's stock worth $56,000 after purchasing an additional 189 shares in the last quarter. MGO One Seven LLC grew its stake in shares of CVS Health by 4.2% in the fourth quarter. MGO One Seven LLC now owns 21,484 shares of the pharmacy operator's stock valued at $964,000 after buying an additional 868 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in CVS Health by 14.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,366,403 shares of the pharmacy operator's stock worth $600,019,000 after buying an additional 1,660,321 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Price Performance

Shares of CVS traded down $0.41 during trading hours on Monday, hitting $64.91. 7,700,036 shares of the company were exchanged, compared to its average volume of 11,825,202. The company has a market cap of $81.84 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 0.98 and a beta of 0.57. The firm's fifty day moving average is $66.48 and its 200 day moving average is $58.77. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $71.45. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, equities analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.10%. CVS Health's dividend payout ratio is currently 72.68%.

Insider Buying and Selling at CVS Health

In other news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares of the company's stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.22% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Evercore ISI lifted their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Monday, January 27th. Robert W. Baird boosted their price target on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Wells Fargo & Company raised their price objective on CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Barclays increased their price target on CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Truist Financial upped their price objective on shares of CVS Health from $76.00 to $82.00 and gave the company a "buy" rating in a report on Friday, April 11th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $71.83.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.